530153 Sigma-AldrichJAK2 Inhibitor X, FLLL32 - 1260115-54-5 - Calbiochem
A cell permeable analog of curcumin that acts as a specific inhibitor of JAK2 (~ 5 µM) and blocks STAT3 phosphorylation in MDA-MB-231 and PANC-1 cancer cells.
More>> A cell permeable analog of curcumin that acts as a specific inhibitor of JAK2 (~ 5 µM) and blocks STAT3 phosphorylation in MDA-MB-231 and PANC-1 cancer cells. Less<<Synonyms: STAT3 Signaling Inhibitor, FLLL32
Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| CAS # | Empirical Formula |
|---|---|
| 1260115-54-5 | C₂₈H₃₂O₆ |
Pricing & Availability
| Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
|---|---|---|---|---|---|---|
| 5.30153.0001 |
|
Glass bottle | 25 mg |
|
— |
| References | |
|---|---|
| References | Wu, J., et al. 2014. Oncogene 33,173. Onimoe, G., et al. 2012. Invest. New Drugs 30, 916. Li, L., et al. 2010. Cancer Res. 70, 2445. |
| Product Information | |
|---|---|
| CAS number | 1260115-54-5 |
| Form | Yellow powder |
| Hill Formula | C₂₈H₃₂O₆ |
| Chemical formula | C₂₈H₃₂O₆ |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | JAK2 |
| Primary Target IC<sub>50</sub> | 5 µ |
| Purity | ≥98% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 5.30153.0001 | 04055977241242 |
Documentation
JAK2 Inhibitor X, FLLL32 - 1260115-54-5 - Calbiochem SDS
| Title |
|---|
References
| Reference overview |
|---|
| Wu, J., et al. 2014. Oncogene 33,173. Onimoe, G., et al. 2012. Invest. New Drugs 30, 916. Li, L., et al. 2010. Cancer Res. 70, 2445. |



